Source:http://linkedlifedata.com/resource/pubmed/id/20452378
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-7-20
|
pubmed:abstractText |
Having recently characterized a CD-1 outbred mouse model of pathogenesis for Western equine encephalitis virus, we examined the possible protective effects of cationic liposome-DNA complexes (CLDCs) against encephalitic arboviral infection. In this investigation, mice were pre-treated, co-treated, or post-treated with CLDC then challenged with a subcutaneous or aerosol dose of the highly virulent WEEV-McMillan strain, lethal in mice 4-5 days after inoculation. Pre-treatment with CLDCs provided a significant protective effect in mice, which was reflected in significantly increased survival rates. Further, in some instances a therapeutic effect of CLDC administration up to 12h after WEEV challenge was observed. Mice treated with CLDC had significantly increased serum IFN-gamma, TNF-alpha, and IL-12, suggesting a strong Th1-biased antiviral activation of the innate immune system. In virus-infected animals, large increases in production of IFN-gamma, TNF-alpha, MCP-1, IL-12, and IL-10 in the brain were observed by 72h after infection, consistent with neuroinvasion and viral replication in the CNS. These results indicate that strong non-specific activation of innate immunity with an immune therapeutic such as CLDC is capable of eliciting significant protective immunity against a rapidly lethal strain of WEEV and suggest a possible prophylactic option for exposed individuals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cytokines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1872-9096
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2010 Elsevier B.V. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
87
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
195-203
|
pubmed:meshHeading |
pubmed-meshheading:20452378-Animals,
pubmed-meshheading:20452378-Blood,
pubmed-meshheading:20452378-Brain,
pubmed-meshheading:20452378-Cytokines,
pubmed-meshheading:20452378-DNA,
pubmed-meshheading:20452378-Disease Models, Animal,
pubmed-meshheading:20452378-Drug Carriers,
pubmed-meshheading:20452378-Encephalitis Virus, Western Equine,
pubmed-meshheading:20452378-Encephalomyelitis, Equine,
pubmed-meshheading:20452378-Female,
pubmed-meshheading:20452378-Immunologic Factors,
pubmed-meshheading:20452378-Immunotherapy,
pubmed-meshheading:20452378-Liposomes,
pubmed-meshheading:20452378-Mice,
pubmed-meshheading:20452378-Survival Analysis
|
pubmed:year |
2010
|
pubmed:articleTitle |
Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge.
|
pubmed:affiliation |
Division of Vector-Borne Infectious Diseases, Centers for Disease Control, Fort Collins, CO 80521, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|